Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | QPCT | Q16769 | 2/20 | 0.42 |
| ▸ | BCL2 | P10415 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 5/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21801464 | 0.90 | BCL2 (0.47) | CNR1QPCTBCL2GSK3BSIRT1 | |
| SCHEMBL21801468 | 0.88 | QPCT (0.42) | QPCTBCL2GSK3BKDRFLT1 | |
| SCHEMBL21801490 | 0.86 | QPCT (0.44) | CNR1QPCTBCL2GSK3BKDR | |
| SCHEMBL21801526 | 0.78 | CDC7 (0.48) | CNR1QPCTSIRT1 | |
| SCHEMBL21801534 | 0.77 | BCL2 (0.44) | BCL2GSK3BCA12CA1CA2 | |
| SCHEMBL21801452 | 0.77 | SIRT1 (0.44) | CNR1SIRT1 | |
| SCHEMBL21801557 | 0.76 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL21801499 | 0.75 | BCL2 (0.50) | QPCTBCL2GSK3BCA12CA1 | |
| SCHEMBL21801541 | 0.74 | QPCT (0.47) | QPCTBCL2GSK3BKDRFLT1 | |
| SCHEMBL21801466 | 0.69 | MAPT (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220257569-A1 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2022-08-18 | — | — | US | disclosed |
| WO-2020051707-A1 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220257569-A1 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE | CNR2, GPR119, CNR1 | CNR1 3/4885QPCT 2631/4885BCL2 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.